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Abstract 
A glass solution of the amorphous sodium salt of furosemide (ASSF) and polyvinylpyrrolidone (PVP) (80:20 
w/w%) was prepared by spray drying. It was investigated if PVP was able to stabilise ASSF during storage 
and dissolution and whether this influenced the in vivo performance of the glass solution after oral dosing 
to rats.  
The glass solution had a glass transition temperature of 121.3±0.5°C, which was significantly higher than 
that of the pure drug (101.2°C). ASSF in the glass solution was stable for at least 168 days when stored at 
20°C and 0% relative humidity. The glass solution exhibited fast dissolution in simulated intestinal medium, 
pH 6.5; the intrinsic dissolution rate was found to be 10.1±0.6 mg/cm2/min, which was significantly faster 
than the pure ASSF. When investigating the stability during dissolution in stimulated intestinal medium at 
pH 6.5, the ASSF in the glass solution showed signs of crystallinity after 1 min of dissolution, but crystallised 
to a lesser extent than pure ASSF. The stabilising effect of PVP on ASSF, led to improved relative oral 
bioavailability in rats of 263%, when compared to the pure ASSF.  
 
Keywords: Furosemide, polyvinylpyrrolidone, glass solution, solid dispersion, amorphous, oral 
bioavailability  
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1. Introduction   
Furosemide, a loop diuretic, is widely used orally for treatment of hypertension and oedema (Goud et al., 
2011; Matsuda et al., 1990). Furosemide is classified as class IV in the Biopharmaceutics Classification 
System (BCS), hence it has a low aqueous solubility in the physiological pH range (5-20 µg/ml) and at the 
same time, a poor intestinal permeability. The compound has weak acidic properties, two pKa values of 9.9 
and 3.5 and is reported to be able to exist in seven different solid state forms: four polymorphs (I, II, III, IV), 
two solvates (IV-DMS and V-dioxane) and one amorphous form (Goud et al., 2011; Granero et al., 2010; 
Matsuda et al., 1990). The poor solubility of furosemide together with a tendency to undergo site-specific 
absorption in the stomach and upper small intestine, leads to a highly variable bioavailability of orally-
administered furosemide in humans (20–60%) (Iannuccelli et al., 2000).  
To decrease variability and increase the overall oral bioavailability, it can be a useful strategy to improve 
the solubility and dissolution rate by converting the crystalline drug to its amorphous forms (Hancock and 
Zograf, 1997). The amorphous form of a drug lacks the three-dimensional long range order of molecular 
packing and is therefore, thermodynamically in a higher energetic state compared to its crystalline 
counterpart. This leads to a higher solubility and faster dissolution rate, but it also results in physical 
instability of the drug with a tendency to convert to a lower energy state (metastable or stable crystalline 
form) over time (storage and/or during dissolution) (Bates et al., 2006; Bikiaris, 2011; Hancock and Zograf, 
1997). For furosemide, it was found that by utilising spray drying, an amorphous sodium salt of furosemide 
(ASSF) can be created (Nielsen et al., 2013a). ASSF exhibited a higher solubility at pH 6.5 together with 20 
and 8-fold faster dissolution rate, when compared to the crystalline and amorphous acid forms of 
furosemide, respectively (Nielsen et al., 2013a). Moreover, the stability of ASSF during storage was found to 
be significantly longer compared to the amorphous acid form (Nielsen et al., 2013a). However, despite 
showing very promising in vitro properties, there was no significant difference in the oral bioavailability 
when ASSF was dosed orally to rats compared to the crystalline and amorphous acid forms of furosemide. 
Although ASSF led to a faster time to peak concentration (Tmax), most likely related to the fast dissolution 
rate of the drug when compared to the two acid forms of furosemide (Nielsen et al., 2013a). The similar 
oral bioavailability of the three forms of furosemide may be explained by the conversion of ASSF to a 
trihydrate of furosemide during dissolution at pH 6.5 (Nielsen et al., 2013b).  
In an attempt to stabilise undissolved ASSF during dissolution, solid dispersions have been investigated in 
the present study. The term solid dispersions has been defined as a dispersion of one or more active 
pharmaceutical ingredient (API) in an inert carrier or matrix. The formation of the solid dispersions (and 
more specifically glass solutions, i.e. single phase molecular dispersions of a drug in a polymer) has become 
one of the preferred methods to enhance drug dissolution and to stabilise the amorphous form of a drug 
(Chiou and Riegelman, 1971; Laitinen et al., 2013). The drug is dispersed in a polymer on a molecular level 
and a single homogeneous amorphous solid is formed, in many cases aided by drug-polymer intermolecular 
interactions (e.g. the formation of hydrogen bonds between the drug and polymer) (Patterson et al., 2005; 
Vasconcelos et al., 2007). The capability of the polymer to inhibit crystallisation of the amorphous form has 
been reported to be possible also at low polymer concentrations (Van den Mooter et al., 2001), and 
nucleation and crystal growth of the amorphous drug is inhibited by the intermolecular interactions. The 
ability of polymers to inhibit crystallisation of the amorphous drug can be linked to the increase in the glass 
transition temperature (Tg) of the glass solution compared to that of the pure amorphous drug, leading to a 
decrease in drug mobility (Hancock and Zograf, 1997; Newman et al., 2011; Van den Mooter et al., 2001).  
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Solid dispersions of furosemide at various concentrations of hydroxypropylmethylcellulose (HPMC) were 
previously studied to investigate if HPMC was able to stabilise ASSF during dissolution (Nielsen et al., 
2013c). It was found that 80 w/w % HPMC was necessary to stabilise ASSF during dissolution as solid 
dispersions containing 20 and 50 w/w % HPMC resulted in conversion of ASSF to a more stable crystalline 
form within 1 min of dissolution at pH 6.5 (Nielsen et al., 2013c). 
Besides cellulose based polymers, such as HPMC, poly(vinyl pyrrolidone) (PVP) is also widely utilised to 
prepare solid dispersions (and especially glass solution) (Alves et al., 2014; Newman et al., 2011). PVP is a 
hydrophilic polymer and is known to inhibit crystal growth and phase transformation (Akbuga et al., 1988; 
Paudel et al., 2013).  Every drug will have different affinity to different polymers, and PVP has shown to 
have a strong hydrogen bonding capacity for example to felodipine (Konno and Taylor, 2006), but is also 
reported to be a useful component in solid dispersions with furosemide (Doherty and York, 1987). 
Furthermore, it is reported in the literature that the chain length of PVP significantly influences the 
dissolution rate of furosemide with PVP K30 providing the fastest dissolution rate compared to other PVP 
types (Akbuga et al., 1988). PVP K30 has also been shown to increase the physical stability of amorphous 
efavirenz (Alves et al., 2014), and it was also reported that solid dispersions with celecoxib and PVP K30 led 
to increased dissolution rate (Homayouni et al., 2014) and in addition a higher oral bioavailability compared 
to the pure drug (Ha et al., 2014). 
The purpose of this study was to investigate if the stability during storage and dissolution of ASSF was 
improved when producing a glass solution of ASSF and PVP. Furthermore, it was studied if the oral in vivo 
performance of ASSF was enhanced in rats by use of the glass solution. 
 
2. Materials and methods 
2.1 Materials 
Furosemide (˃98% purity) and taurocholic acid sodium salt hydrate (sodium taurocholate) were acquired 
from Sigma-Aldrich (St. Louis, MO, USA). Polyvinylpyrrolidone (PVP K30) was obtained from Unikem 
(Copenhagen, Denmark), and phosphatidylcholine (Lipoid S PC, purity ≥ 98%) was purchased from Lipoid AG 
(Ludwigshafen, Germany). Sodium azide and potassium dihydrogen phosphate were obtained from Merck 
(Darmstadt, Germany). Ultra-purified water was obtained from an SG Ultra Clear water system (SG Water 
USA, LLC, Nashua, NH, USA) and was freshly produced in all cases.  All other chemicals employed were of 
analytical grade.   
 
2.2 Preparation and manufacturing of the glass solution containing furosemide and PVP  
In order to formulate the glass solution containing furosemide and PVP (80:20 w/w%), the two compounds 
were mixed and dissolved in purified water at pH 10 (adjusted with NaOH). The solution was stirred 
overnight and spray dried the following day on a Büchi Mini Spray-Dryer B-290 (Büchi Labortechnik AG, 
Flawil, Switzerland) in a similar set-up as described previously (Nielsen et al., 2013c).  A 0.7-mm nozzle was 
utilised for the spray drying process with air as the drying medium. Relevant spray drying parameters are 
listed in Table 1. Following completion of the process, the product was collected and stored in a glass vial 
protected from light.  
 
Table 1: Process parameters for spray drying of the furosemide and PVP glass solution 
Process parameters Furosemide and PVP glass solution 
Inlet temperature (°C) 185±5 
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Outlet temperature (°C) 78±3 
Aspirator rate (%) 80 
Drying flow rate (m3/h) 32  
Pump flow rate (mL/min) 3.6  
 
2.3 Characterisation of furosemide in the glass solution by X-ray powder diffraction (XRPD) 
Following the spray drying process, XRPD was performed to determine the solid state form of furosemide in 
the formulation. Moreover, XRPD was used to confirm the solid state form after storage and dissolution. 
XRPD analyses were performed using an X'Pert PRO X-ray diffractometer (PANalytical, Almelo, The 
Netherlands; MPD PW3040/60 XRD; Cu KR anode; λ = 1.541 Å; 45 kV; 40 mA). A starting angle of 5° 2θ and 
an end angle of 35° 2θ were utilised for the scans with a scan speed of 0.6565° 2θ /min and a step size of 
0.01313° 2θ. Data were collected using X’Pert Data Collector software (PANalytical B.V.) 
 
2.4 Measurement of glass transition temperature (Tg) by differential scanning calorimetry (DSC) 
DSC experiments were performed using a Discovery DSC 1-0216 (TA instruments, New Castle, DE, USA), 
operated with TRIOS software (version 3.0.1.3156). The glass solution (4-5 mg) was weighed into aluminium 
pans and sealed with pin-holed lids. A heating rate of 10 K/min was employed, measuring from 10-200°C at 
a nitrogen flow rate of 20 mL/min.  
 
2.5 Biorelevant intestinal dissolution medium  
Release of ASSF from the formulation was investigated in simulated intestinal medium, pH 6.5. The medium 
contained 10 mM of sodium taurocholate as the bile salt and 2.5 mM of phosphatidylcholine as the 
phospholipid and was prepared as previously described (Nielsen et al., 2013a, 2013b).  
 
2.6 Biorelevant dissolution and intrinsic dissolution rate (IDR) of ASSF from the glass solution 
Release and dissolution of ASSF from the glass solution was investigated on a µDISS profiler (pION INC, 
Woburn, MA), with simulated intestinal medium as the release medium. Dissolution experiments were 
performed at 37±0.5°C using a stirring rate of 100±3 rpm. 1 mm path length in situ UV probes were 
employed on a µDISS profiler. Each channel was calibrated with its own standard curve prior to 
experiments. For the calibration curves, aliquots of furosemide in water stock solution were repeatedly 
added to 10 mL of the simulated medium in order to achieve a range of defined standard concentrations, 
and the UV spectrum of each standard was recorded. The release experiments were performed both from 
powder (to obtain total release) and from compacts (for calculation of the intrinsic dissolution rate (IDR)). 
Accurately weighed 8-10 mg of the glass solutions was used for both sets of experiments. For the compact 
experiments miniaturized pellets of the glass solutions were then prepared using a Mini-IDR compression 
system (Heath Scientific, UK), and the pellet was compressed in the stainless steel die at 80 bar for 40 s to 
produce a uniform flat surface. The sample dies were placed into cylindrical magnetic stirring bars, and 
covered with 10 mL of release medium. For the powder experiments, the weighted powder was added to 
sample vials and covered with 10 mL of release medium. The release for both sets of experiments was 
measured by recording of UV spectra in individual channels for a total period of 180 min. Dissolved 
furosemide concentrations were then determined by analysing recorded spectra at a wavelength range of 
310-350 nm, with reference to the created calibration curves. PVP did not give any UV signal in this range. 
Release profiles of the glass solutions were collected in three replicates. 
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For calculation of release and IDR of ASSF in the glass solution, the coefficient of determination (R2) from 
linear regression analysis was used to assess the quality of the fit of standard curves (described above) for 
IDR measurements. From the µDISS software, release curves with the concentration of released furosemide 
as a function of time were determined. The initial linear slope from the release curves was then used to 
calculate IDR, by employing the Noyes-Whitney equation (Avdeef and Tsinman, 2008; Noyes and Whitney, 
1897).  
 
2.7 Stability investigations during storage and dissolution of ASSF in the glass solution by XRPD 
The physical stability of ASSF in the glass solution was studied by storing the formulation at 20±3°C and 0% 
relative humidity (RH). The ASSF in the glass solution was regularly inspected for its solid state form using 
XRPD (settings are described in section 2.3) for up to 168 days. 
For investigation of the solid state form of furosemide in the glass solutions during release, µDISS 
experiments were also performed from compacts (as detailed in section 2.6) for shorter time periods of 1, 
3, 5, 10, 20, and 30 min. Prior to and following experiments, drug compacts were analysed by XRPD (see 
section 2.3).  
 
2.8 Oral in vivo study in rats of the glass solution and of pure ASSF 
All animal care and experimental studies were approved by the Animal Welfare Committee, appointed by 
the Danish Ministry of Justice, and were carried out in compliance with EC Directive 2010/63/EU, the 
Danish law regulating experiments on animals and NIH Guidelines for the Care and Use of Laboratory 
Animals. The experiments were performed under the following license: 2012−15−2934−00186. The 
experimental animal work was performed at the Department of Experimental Medicine, University of 
Copenhagen, Denmark, which is accredited by the Association of Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). 
Male Sprague-Dawley rats (314-342 g on the experimental day) were purchased from Taconic (Bomholt, 
Denmark). Animals were acclimatised for a minimum of 7 days in groups of two on wooden bedding 
(Tapvei, Kortteinen, Finland) in plastic cages on standard feed (Altromin 1324, Altromin Spezialfutter, Lage, 
Germany) and carrots, with free access to fresh tap water in an air-conditioned building with controlled 
environmental parameters (humidity 40-60%, temperature 20 ± 1°C, light from 6am-6pm). Before entry 
into the experiments, the animals were fasted for approximately 6 hours and randomly assigned to receive 
one of the treatments. During the experiments, water was freely available. 
The glass solution and the pure ASSF (both prepared one day prior to the experiment) were administered 
orally to the rats in gelatine capsules, size 9 (Torpac, NJ, USA). One day prior to the in vivo experiment, the 
capsules were filled with 4.5 mg of ASSF (corresponding to 5.4 mg of the glass solution) per capsule (equal 
to approximately 15 mg/kg dosed to the rats), by placing the bottom of the capsule in a stand and filling via 
a funnel. The capsules (one capsule per rat) were dosed with a dosing syringe (Torpac, NJ, USA) to the 
bottom of the oesophagus of the rat.  Blood samples (0.2 mL) were taken from the tail vein by individual 
venipuncture and collected into EDTA coated tubes. Samples were collected at 10, 20, 30, 45 min, and 1, 2, 
3, 5, 7, and 24 h after drug administration Plasma was harvested immediately by centrifugation at 13,200 
rpm (12 min) and stored at −20 °C until further analysis. 
The in vivo studies were performed in 5 and 6 replicated for the pure ASSF and the glass solution, 
respectively. 
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2.9 Quantitative analysis of plasma samples by liquid chromatography–mass spectrometry (LC-MS) 
Plasma samples were processed using 30 µl of the plasma spiked with 300 µl of acetonitrile to precipitate 
the proteins. The mixtures were centrifuged at 15,000 rpm for 15 min at room temperature (Heraeus 
Sepatech Biofuge 15). After centrifugation the produced supernatants were transferred to HPLC vials and 
analysed by LC-MS. The LC-MS method was performed using an Agilent technologies 1200 system with a 
6140 Quadrupole detector. Chromatographic separations were performed on a Phenomenex® Kintex C18 
column (4.6 x 100 mm, 5 µm). The samples were eluted with a flow rate of 0.7 mL/min in a gradient 
mixture of 0.04% acetic acid in purified water (solvent A) and acetonitrile (solvent B). The gradient program 
was as follows: 0-2 min, 25% solvent B; 2-3 min, from 25 to 80% solvent B; 3-6 min, 80% solvent B; 6-7 min, 
from 80 to 25% solvent B; 7-10 min, 25% solvent B. The autosampler temperature was kept at 5°C and 
injection volume of the sample was set at 5 μl. The LC-MS method was carried out using nitrogen to assist 
nebulisation. The electrospray ionization source was run in negative ion mode. The operational parameters 
of the ESI source were as follows:  vaporiser temperature: 200°C, gas temperature: 350°C, drying gas flow: 
12 L/min. A capillary potential of 2000 V was employed, and the fragmentor voltage was set to 110 V for 
detector pseudo-molecular ions (328.90 m/z and 329 m/z). 
 
2.10 Pharmacokinetic analyses 
The pharmacokinetic parameters following oral administration of furosemide were obtained by 
noncompartmental analysis. The area under the curve (AUC) of the plasma concentration versus time 
curves was determined by the linear log trapezoidal method from time t = 0 min either to t = 180 min or to 
the last plasma concentration measured at t = 1440 min after dosing. AUC values were used to calculate 
the relative bioavailability. The maximum furosemide plasma concentration (Cmax) and time to peak 
concentration (Tmax) were determined from the individual plasma concentration versus time curves. 
 
2.11 Statistical analysis 
In all cases of the in vitro data, results are expressed as mean ± standard deviation (SD). The in vivo data are 
stated as mean ± standard error of mean (SEM). Where appropriate, statistical analysis was carried out 
using student t-tests. Statistical analyses were carried out using GraphPad Prism version 6.05. P-values 
below 5% (p< 0.05) were considered statistically significant.  
 
3. Results and discussion 
3.1 Glass transition temperature (Tg) of the glass solution 
To investigate if it was possible to stabilise ASSF with polymer especially during dissolution, spray drying 
was utilised as the method for preparing the glass solution. Spray drying is a well-established method when 
preparing glass solutions, and has the advantage of being a one-step process where the fast solvent 
evaporation results in an amorphous form of the drug within the formed glass solution (Bikiaris, 2011; 
Grohganz et al., 2014). 
An essential parameter for characterising the amorphous form of a drug within the glass solution is the Tg 
(here measured by DSC). With respect to amorphous forms in general, a high Tg is a good indicator of an 
increased stability, as it suggests a reduced capability of crystallisation due to a lower molecular mobility 
(Guerrieri et al., 2010). The DSC measurement showed a Tg of the glass solution of 121.3±0.5°C and PVP had 
a Tg of 160.5±0.4°C. It has previously been found that the Tg for ASSF is 101.2°C, hence, there should be a 
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greater stability of ASSF in the glass solution compared to the pure ASSF. The DSC data also showed only a 
single Tg as the only thermal event, indicating molecular miscibility of furosemide and PVP.  
 
3.2 Biorelevant dissolution of ASSF in the glass solution 
When developing a glass solution, it is important that the polymer does not have a negative effect on the 
dissolution and dissolution rate of the drug compared to the drug itself. To investigate the dissolution of 
ASSF in the glass solution, a physiologically relevant dissolution medium was employed to simulate the in 
vivo situation as closely as possible. In Figure 1A it can be observed that the powder dissolution of ASSF in 
the glass solution in the simulated medium at pH 6.5 was very fast and after 1 min, 82.2±5.4% of 
furosemide was dissolved. The dissolution (from powder samples) was measured over a period of 180 min 
(corresponding to the in vivo transit time in the small intestine), and at the end of dissolution 85.6±3.0% of 
furosemide was released and dissolved from the glass solution (Figure 1A). To calculate the IDR of 
furosemide from the glass solution, discs of the glass solution were compressed and the dissolution was 
measured again. The IDR was found to be 10.1±0.6 mg/cm2/min. In a previous study, the IDR for ASSF was 
8.8±0.6 mg/cm2/min (Figure 1B) (Nielsen et al., 2013a), and significant difference was therefore found (p-
value 0.0236). It can therefore be concluded that PVP did affect the dissolution rate of ASSF in a positive 
fashion due to the hydrophilic nature of PVP (Halake et al., 2014). A fast dissolution rate is important for 
developing a good drug formulation of furosemide, and glass solutions will often provide this because of 
the hydrophilic properties of the polymer. When the glass solution is dispersed in water, the carrier will 
generally either dissolve or absorb water very fast facilitating release and dissolution of the drug (Vo et al., 
2013).  
 
 
Figure 1:  A) Dissolution profile of amorphous sodium salt of furosemide (ASSF) from the glass solution. B) 
Intrinsic dissolution rates (IDR) for ASSF in the glass solution and pure ASSF (Nielsen et al., 2013a), 
calculated from the initial slope (1–10 min) of the dissolution curve from disc dissolution. Both experiments 
were performed in simulated medium at pH 6.5. Data represent the mean ± SD of 3 replicates.  
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3.3 Stability of ASSF in the glass solution during storage and dissolution 
In general, amorphous forms of drugs have a tendency to convert to a more stable crystalline form during 
storage and/or dissolution (Hancock and Zograf, 1997), and therefore it is a key point to investigate the 
stability of the amorphous drug in the glass solution.  
The glass solution immediately after spray drying was shown by XRPD to contain the drug in an amorphous 
form (Figure 2). The glass solution was stored at 20°C and 0% RH to investigate the stability of ASSF during 
storage, and from the characteristic halo pattern of the diffractogram in Figure 2, the continued presence 
of ASSF through the whole storage period (168 days) of the glass solution could be confirmed. It is well 
known from the literature that the relative crystallisation tendency of the amorphous drug in the glass 
solution is dependent of the pure drug form (Marsac et al., 2006). Earlier, ASSF has been shown to be stable 
at 22°C and 33% RH for up to 291 days (Nielsen et al., 2013a), hence, it was expected that ASSF in the glass 
solution would still be on its amorphous form after 168 days. There is a good correlation with results from 
the literature. Here it has been reported when storing a glass solution of amorphous furosemide acid and 
PVP at temperatures varying from 6-45°C and 40% RH, no evidence of crystalline furosemide was observed 
over a period of 12 months, based on XRPD measurements (Doherty and York, 1989). Furthermore, a rule 
of thumb is that crystallisation can often be avoided if the amorphous drug is stored at temperatures 50°C 
or more below Tg of the dispersion. At those temperatures, the molecular mobility of the drug is very low 
and therefore, the physical stability is high at these temperatures (Newman et al., 2011). 
 
Figure 2: XRPD diffractograms of the glass solution of amorphous sodium salt of furosemide (ASSF) and PVP 
initially after spray drying and after 168 days of storage at 20˚C and 0% RH. As reference the diffractogram 
of PVP is also shown.  
 
The glass solution used in this study seemed stable during storage, but devitrification is often observed 
during dissolution (Kanaujia et al., 2011; Savolainen et al., 2009). In previous studies, it has been 
problematic to keep the ASSF in its amorphous form during dissolution at pH 6.5 (Nielsen et al., 2013b, 
2013c), and therefore, it is essential to investigate the solid state form of furosemide in the glass solution 
also during dissolution. To investigate this, a dissolution experiment on a µDISS profiler in a simulated 
intestinal medium at pH 6.5 was performed together with off-line XRPD. The compact containing the glass 
solution was investigated on XRPD and already after 1 min of dissolution a small peak was observed in the 
otherwise halo pattern diffractogram (Figure 3). This is an indicator towards that the ASSF in the glass 
solution already converting to a crystalline form after 1 min of dissolution, and in Figure 3 it can be 
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observed that the peaks grow during the 30 min of dissolution. Although, the ASSF in the glass solution 
seems to be partly crystalline during dissolution, this is occurring to a lesser extent compared to the pure 
ASSF.  
 
Figure 3: XRPD of amorphous sodium salt of furosemide (ASSF) in glass solution following 1, 3, 5, 10, 20, 
and 30 min of dissolution on a µDISS profiler in a simulated intestinal medium pH 6.5. Diffractogram of 
ASSF in the glass solution before dissolution is shown for reference.  
 
In a previous study, the devitrification tendency of pure ASSF was tested in a similar set-up to here, and in 
this study ASSF was also found to crystallise after 1 min of dissolution (Nielsen et al., 2013b). For 
comparison, it can be observed that the ASSF in the glass solution crystallise slower than the pure ASSF by 
comparing the peaks at 1 min of dissolution in the diffractograms (taking into account that the ASSF in the 
glass solution contains 20% less ASSF) (Figure 4). After 30 min of dissolution, there are peaks corresponding 
to a crystalline form of furosemide in both the glass solution and for the pure ASSF, but for the pure ASSF 
the peak intensity appears to be slightly higher and several more peaks appear than for the ASSF in the 
glass solution (Figure 4). In the literature, it is found that pure ASSF crystallised to a trihydrate of 
furosemide when in contact with aqueous  medium (Nielsen et al., 2013b). We have not specifically 
investigated to what polymorph the furosemide in the glass solution converted during dissolution but from 
Figure 4 it can be concluded that the drug in the glass solution does not crystallise to its crystalline acid 
form. This means that PVP in the glass solution has a stabilising effect on ASSF and PVP by its characteristic 
of being a crystallisation inhibitor decreases the crystallinity of ASSF in the glass solution. It is found in the 
literature that PVP has previously been able to stabilise amorphous furosemide acid, and it was found that 
1:3 and 1:5 ratios of drug to polymer were the best choice to stabilise the amorphous furosemide acid 
(Iannuccelli et al., 2000). In the current study, the ratio (4:1) is much below that, indicating that PVP even in 
small amounts can stabilise the ASSF both during storage and dissolution. 
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Figure 4:  XRPD of amorphous sodium salt of furosemide (ASSF) in glass solution at 1 and 30 min as found in 
Figure 2 and the XRPD diffractograms for pure ASSF after 1 and 30 min of dissolution in a simulated 
intestinal medium at pH 6.5 (Nielsen et al., 2013b). As reference the diffractogram of crystalline furosemide 
acid has been added.  
 
3.4 Oral in vivo study in rats of the glass solution and of pure ASSF 
As the in vitro studies showed that PVP decreased the crystallinity of ASSF in the glass solution compared to 
the pure ASSF at pH 6.5, an in vivo pharmacokinetic study was performed in rats, in order to assess if this 
was also translated to the in vivo situation. In the literature, it is reported that a glass solution will not 
influence on the permeability properties of a drug (Miller et al., 2012), and therefore it is believed that the 
in vivo data can be interpreted based on the dissolution data. Figure 5 shows the mean plasma 
concentration versus time profiles for the two ASSF formulations, and the noncompartmental 
pharmacokinetic parameters are provided in Table 2. The oral dosing of the ASSF formulations resulted in 
no significant difference (p-value 0.7447) in the Tmax value. Even though IDR values are expected to be 
closely related to the in vivo drug dissolution dynamics  (Yu et al., 2004), the difference in the IDR values in 
the in vitro studies of the ASSF in the glass solution compared to pure ASSF, did not reflect in a significant 
difference in the Tmax values. In terms of the Cmax and AUC0-180 min, no significant difference was observed 
between the two formulations (p-value 0.5438 and p-value 0.3939, respectively). However, a greater AUC0-
1440 min was found for ASSF in the glass solution, compared to pure ASSF (p-value 0.0449). Figure 5 reveals 
that the difference in AUC starts to set in after approximately 120 min and continues until the end of the 
experiment (1440 min). The higher AUC for the glass solution also led to a higher relative bioavailability of 
the ASSF in the glass solution compared to pure ASSF of 262.7%. Assuming that the absorption kinetics for 
ASSF in the glass solution and for pure ASSF are identical, the difference in the higher AUC for the ASSF in 
the glass solution can be explained by that the ASSF in the glass solution having a lower tendency to 
crystallise during dissolution compared to pure ASSF resulting in a longer absorption phase. In general, it is 
found that there is a good correlation between humans and rats in terms of oral absorption of drugs (Chiou 
et al., 2000), and therefore the ASSF and PVP glass solution could be a promising formulation for 
furosemide in terms of a higher bioavailability compared to the pure ASSF and crystalline furosemide acid 
(Nielsen et al., 2013a).  
11 
 
 
Figure 5: Plasma concentrations of the glass solution and pure amorphous sodium salt of furosemide (ASSF) 
dosed in gelatin capsules orally to rats. Data represent mean±SEM, with n=5-6.  
 
Table 2: Noncompartmental pharmacokinetic parameters of the glass solution and pure amorphous sodium 
salt of furosemide (ASSF) following oral administration to rats. Data represent mean±SD, with n=5-6.  
 Glass solution Amorphous sodium salt 
of furosemide (ASSF) 
Tmax (min) 38.3±5.9 36.0±3.7 
Cmax (µg/mL) 3.5±0.4 3.9±0.6 
AUC0-180 min 436.1±64.5 373.0±24.6 
AUC0-1440 min 2169.1±529.2 736.3±61.1 
Relative bioavailability (%)1 262.7±177.1 
 
- 
1Relative bioavailability was determined as: 100x(AUCglass solution/doseglass solution)/(AUCASSF/doseASSF) 
 
5. Conclusion 
A glass solution of ASSF and PVP (80:20 w/w%) has been prepared by spray drying. The Tg of the glass 
solution was found to be higher than the Tg for the pure ASSF, and in addition, IDR for the glass solution 
was found to be faster than for the pure ASSF. PVP was shown to be able to stabilise the amorphous form 
of furosemide during storage (for 168 days) and PVP decreased the crystallisation tendency of ASSF 
compared to pure ASSF during dissolution in a simulated medium at pH 6.5. This led to a relative oral 
bioavailability of the glass solution of 262.7% compared to ASSF when dosed orally to rats. These results 
show that the ASSF has potential as a drug formulation for oral delivery of furosemide and would possibly 
increase the oral bioavailability of furosemide in humans.    
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